Answers are grounded in this paper and cite their sources.
Conventional two-dimensional cell lines and animal models each present well-recognized limitations for studying human viral infection: monolayer cultures lack tissue-level architecture and cellular heterogeneity, while species differences in receptor expression and immune physiology limit the translatability of animal data to human disease. Three-dimensional in vitro models, including air-liquid interface (ALI) transwell cultures, adult stem cell- and pluripotent stem cell-derived organoids, and microfluidic organ-on-chip platforms, have emerged as physiologically relevant alternatives that better recapitulate human tissue architecture, cellular diversity, and host-pathogen interactions. This review examines the application of these three-dimensional platforms across six domains of human viral pathogenesis: respiratory viruses (influenza, SARS-CoV-2, rhinovirus, respiratory syncytial virus) studied using ALI airway cultures, airway/lung/nasal organoids, and alveolar-capillary organ-on-chip systems; hepatotropic viruses (hepatitis B and C viruses) studied using perfused microfluidic liver cultures and patient-derived liver organoids capable of supporting complete viral replication cycles; enteric viruses (rotavirus, norovirus, coxsackievirus) studied using human intestinal enteroids and gut-on-chip systems; hemorrhagic-fever viruses (Ebola, Lassa) studied using microvessel-on-chip platforms; cardiotropic SARS-CoV-2 infection studied using engineered heart tissue; and neurotropic TORCH viruses (Toxoplasma, Other agents, Rubella, Cytomegalovirus, Herpes simplex virus - here represented by Zika virus and herpes simplex virus 1) studied using human brain organoids that recapitulate virus-induced microcephaly phenotypes. We compare the architecture, quantitative performance, strengths, and limitations of twenty-one representative platforms, position six platform classes on a physiological-relevance-versus-throughput landscape, summarize demonstrated applications in antiviral drug screening (including chip-based identification of amodiaquine and nafamostat repurposing candidates and a clinically important hydroxychloroquine false-positive), and extend the discussion to the translational challenges of donor variability, cross-laboratory standardization, throughput, and immune-cell integration that currently limit broader adoption of these models in preclinical virology and drug discovery pipelines.
No takes yet. Share an insight, caveat, or question.
Uchino et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: